These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 17409432

  • 1. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Maloney A, Clarke PA, Naaby-Hansen S, Stein R, Koopman JO, Akpan A, Yang A, Zvelebil M, Cramer R, Stimson L, Aherne W, Banerji U, Judson I, Sharp S, Powers M, deBilly E, Salmons J, Walton M, Burlingame A, Waterfield M, Workman P.
    Cancer Res; 2007 Apr 01; 67(7):3239-53. PubMed ID: 17409432
    [Abstract] [Full Text] [Related]

  • 2. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
    Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P.
    J Natl Cancer Inst; 1999 Nov 17; 91(22):1940-9. PubMed ID: 10564678
    [Abstract] [Full Text] [Related]

  • 3. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.
    Siegel D, Shieh B, Yan C, Kepa JK, Ross D.
    J Pharmacol Exp Ther; 2011 Mar 17; 336(3):874-80. PubMed ID: 21156818
    [Abstract] [Full Text] [Related]

  • 4. Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.
    Zajac M, Gomez G, Benitez J, Martínez-Delgado B.
    BMC Med Genomics; 2010 Oct 04; 3():44. PubMed ID: 20920318
    [Abstract] [Full Text] [Related]

  • 5. HSP27 expression levels are associated with the sensitivity of hepatocellular carcinoma cells to 17-allylamino-17-demethoxygeldanamycin.
    Cui Y, Wu W, Zhou Y, Xie Q, Liu T, Jin J, Liu K.
    Future Oncol; 2013 Mar 04; 9(3):411-8. PubMed ID: 23469976
    [Abstract] [Full Text] [Related]

  • 6. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
    Tse AN, Sheikh TN, Alan H, Chou TC, Schwartz GK.
    Mol Pharmacol; 2009 Jan 04; 75(1):124-33. PubMed ID: 18820127
    [Abstract] [Full Text] [Related]

  • 7. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
    Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P, Ronen SM.
    J Natl Cancer Inst; 2003 Nov 05; 95(21):1624-33. PubMed ID: 14600095
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Study on signal transduction pathway in differentiation and apoptosis of leukemia cells induced by heat shock protein inhibitor].
    Yu WJ, Rao Q, Wang M, Tian Z, Xu ZF, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct 05; 28(10):677-80. PubMed ID: 18399173
    [Abstract] [Full Text] [Related]

  • 11. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM.
    Cancer Chemother Pharmacol; 2005 Aug 05; 56(2):126-37. PubMed ID: 15841378
    [Abstract] [Full Text] [Related]

  • 12. p53 independent radio-sensitization of human lymphoblastoid cell lines by Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Fujii Y, Kato T, Kubota N, Fujimori A, Niwa O, Okayasu R.
    Oncol Rep; 2010 Jan 05; 23(1):199-203. PubMed ID: 19956882
    [Abstract] [Full Text] [Related]

  • 13. Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.
    Huntoon CJ, Nye MD, Geng L, Peterson KL, Flatten KS, Haluska P, Kaufmann SH, Karnitz LM.
    Cancer Res; 2010 Nov 01; 70(21):8642-50. PubMed ID: 20841485
    [Abstract] [Full Text] [Related]

  • 14. Topically applied Hsp90 inhibitor 17AAG inhibits UVR-induced cutaneous squamous cell carcinomas.
    Singh A, Singh A, Sand JM, Bauer SJ, Hafeez BB, Meske L, Verma AK.
    J Invest Dermatol; 2015 Apr 01; 135(4):1098-1107. PubMed ID: 25337691
    [Abstract] [Full Text] [Related]

  • 15. [Influence of 17AAG on proliferation and invasion of gastric cancer cell and its mechanism].
    Cui Y, Yu Y, Liu T, Xie Q, Wu W, Liu K.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Oct 01; 17(10):1031-5. PubMed ID: 25341914
    [Abstract] [Full Text] [Related]

  • 16. Heat shock protein 90 inhibitor attenuates renal fibrosis through degradation of transforming growth factor-β type II receptor.
    Noh H, Kim HJ, Yu MR, Kim WY, Kim J, Ryu JH, Kwon SH, Jeon JS, Han DC, Ziyadeh F.
    Lab Invest; 2012 Nov 01; 92(11):1583-96. PubMed ID: 22964853
    [Abstract] [Full Text] [Related]

  • 17. Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells.
    Myung SJ, Yoon JH, Kim BH, Lee JH, Jung EU, Lee HS.
    J Pharmacol Exp Ther; 2009 Jul 01; 330(1):276-82. PubMed ID: 19329756
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Inhibition of Heat Shock Protein 90 suppresses TWIST1 Transcription.
    Chong KY, Kang M, Garofalo F, Ueno D, Liang H, Cady S, Madarikan O, Pitruzzello N, Tsai CH, Hartwich TMP, Shuch BM, Yang-Hartwich Y.
    Mol Pharmacol; 2019 Aug 01; 96(2):168-179. PubMed ID: 31175180
    [Abstract] [Full Text] [Related]

  • 20. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
    Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, Brufsky AM, Wong MK, Tutchko S, Egorin MJ.
    Clin Cancer Res; 2005 May 01; 11(9):3385-91. PubMed ID: 15867239
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.